BIOMEDICAL RESEARCH INSIGHTS

洞察前沿,连接科研新知

聚焦合成生物学、AI 靶点发现、临床队列与公共数据库,汇集最新论文摘要与原始出处
每 12 小时采集更新,经人工审核后发布。

前沿研究专业聚合持续更新
PAPER EXPLORER

发现热点论文

每 5 分钟更新缓存
全部共 142 篇
合成生物学基础研究Nucleic acids research

Multi-level precise regulation of gene transcription in the yeast Saccharomyces cerevisiae based on light-sensitive CRISPR/Cas systems.

0 次引用趋势数据不足

基于CRISPR的基因转录调控是构建酿酒酵母合成基因电路的重要工具,但现有策略多局限于单一调控层面,灵敏度有待提高。本研究将翻译水平和翻译后水平的基因调控方法与光遗传学控制模式相结合,实现对dCas9蛋白的高灵敏多层级精准调控,从而灵活调节靶基因转录水平。利用该策略调控荧光蛋白转录水平,mCherry荧光强度较无调控时最高提升2.58倍。该基于CRISPR的多层级光遗传学系统有助于理解基因调控网络,并为合成生物学设计稳健的基因电路提供支持。

为什么值得关注

暂未整理

查看扩展信息

完整作者

Yaokun Liang、Xianghui Qi、Song Gao、Yunjiao Wang、Guoshi Kan、Leonid N Valentovich、Jingjing Guo、Yingfeng An

作者机构

  • College of Biosciences and Biotechnology, Shenyang Agricultural University, Shenyang 110866, Liaoning, China.
  • Shenyang Key Laboratory of Microbial Resource Mining and Molecular Breeding, Liaoning 110000, Shenyang, China.
  • School of Life Sciences, Guangzhou University, Guangzhou, Guangdong 510006, China.
  • Institute of Microbiology, National Academy of Sciences of Belarus, Minsk 220000, Belarus.
  • Engineering Research Centre of Applied Technology on Machine Translation and Artificial Intelligence, Macao Polytechnic University, Macau 999078, China.

技术路线

以荧光蛋白为报告基因→基于光敏CRISPR/dCas9系统,整合翻译与翻译后水平的调控模式,对dCas9蛋白实施多层级精准调控,分析目标基因转录水平变化(mCherry荧光强度较无调控提升最高2.58倍)

最近 5 个完整年度引用趋势

0110202102022020230202402025

不含 2026 年,仅展示最近 5 个完整年度。

数据来源:openalex更新时间:2026/10/30 06:00
AI 靶点发现研究类型未标注Chinese herbal medicines

Advancing TCM-derived active natural product drug discovery for novel drug targets: Insights from AI powered tools.

暂无引用数据

针对尚未充分探索的新型生物靶点发现天然产物至关重要,是推动多类疾病创新疗法发展的基础。随着人工智能(AI)快速发展及多组学整合、网络靶点预测、虚拟筛选、药物-靶点相互作用预测等药物发现策略的应用,中药来源活性天然产物药物发现进入新阶段,多模态高维数据可在大数据背景下整合,提升理论基础与技术能力。但AI驱动的天然产物药物发现仍面临数据与研究质量保障及实现更深入科学发现等重大挑战,需进一步创新以获得更精准且具有生物医学意义的结果。整合高维数据、网络建模与智能筛选,并置于闭环验证框架中,有望推动AI与大数据范式促进生物活性成分的精准发现,为复杂疾病的靶向治疗开辟新前沿。

为什么值得关注

暂未整理

查看扩展信息

完整作者

Shangtao Wang、Jinling Zhang、Wenshuang Wang、Sihan Xu、Man Zhang、Yuanyuan Hou、Gang Bai

作者机构

  • College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research. State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin 300350, China.

技术路线

暂未整理

最近 5 个完整年度引用趋势

暂无引用数据

数据来源:暂未标注更新时间:暂无更新时间
临床队列临床研究Paediatrics & child health

A prospective cohort study of serum sickness-like reactions in the pediatric population.

0 次引用趋势数据不足

一项前瞻性队列研究于2022年10月至2024年9月在加拿大伦敦儿童医院开展,纳入0至18岁表现为皮疹伴关节痛或水肿的患儿,旨在描述儿童血清病样反应(SSLR)的临床与实验室特征。27例患者中男性占59%,就诊时平均年龄4岁;阿莫西林是最常见诱因(85.2%),皮疹以环状形态最常见,超声排除了真性关节炎。皮疹约5天消退,关节痛约4天缓解;全身性激素可加速关节痛缓解,但未缩短病程。淋巴细胞毒性试验在58.3%的病例中确认药物因果关系,并与环状皮疹及T细胞活化标志物升高相关。研究认为,上述发现对儿童SSLR的诊断、管理和预后具有重要意义。

为什么值得关注

暂未整理

查看扩展信息

完整作者

暂未整理

作者机构

暂未整理

技术路线

暂未整理

最近 5 个完整年度引用趋势

0110202102022020230202402025

不含 2026 年,仅展示最近 5 个完整年度。

数据来源:openalex更新时间:2026/10/31 11:42
公共数据库基础研究Acta pharmaceutica Sinica. B

Oral artificial microbio-vaccine triggers synergistic immunogenic cell death induction and tumor microenvironment remodeling for liver cancer therapy.

暂无引用数据

研究人员采用分层组装策略构建了一种口服人工微生物疫苗(TP/GA-NYPs):将免疫原性细胞死亡诱导剂雷公藤甲素(TP)与免疫调节剂甘草酸(GA)共组装为纳米解毒核心,并负载于中空酿酒酵母微胶囊(YC)中,壳聚糖外壳保障包封效果。该设计利用YC实现胃部保护和肠道黏膜靶向。结果显示,TP/GA核心具有协同作用,TP有效诱导免疫原性细胞死亡,GA则通过抑制转移相关标志物、增强免疫刺激性细胞因子谱重塑免疫抑制性肿瘤微环境。该口服聚集体可激发肠道黏膜及全身免疫,抑制肝癌进展与转移,并减轻TP的全身毒性。研究提示功能性聚集体在协同抗肿瘤免疫方面具有治疗潜力,为口服免疫治疗提供了通用平台。

为什么值得关注

暂未整理

查看扩展信息

完整作者

暂未整理

作者机构

暂未整理

技术路线

暂未整理

最近 5 个完整年度引用趋势

暂无引用数据

数据来源:暂未标注更新时间:暂无更新时间
AI 靶点发现综述Nature

Towards the construction of a virtual yeast.

5 次引用趋势数据不足

为推进细胞生命的计算模拟,研究者提出“虚拟酵母”——一种由人工智能驱动的代理,以酿酒酵母为遗传可操作、数据丰富的模式系统,通过整合多模态生物学数据、机制推理与主动实验来模拟真核细胞行为。该系统将细胞复杂性分解为遗传、代谢和结构系统等八个以功能为中心的模块,每个模块由领域专用AI工具实现,并通过基于大语言模型的编排层协调。系统以机制知识、亚细胞结构和动态状态三大数据支柱为基础,在闭环学习流程中整合表征学习与生成建模,自主设计和执行实验。虚拟酵母可作为优化生物合成通路、支持多种细胞过程假设生成与优先级排序以及加速靶点发现的概念与操作平台,为构建虚拟真核细胞和推进合成生物学提供可推广的蓝图。

为什么值得关注

暂未整理

查看扩展信息

完整作者

Liujia Qian、Zizhuo Zhou、Peijie Zhou、Zhen Dong、Xudong Zhang、Zhenwu Dai、Zhangyang Gao、Siqi Sun、Kevin R Roy、Shuaiyao Wang、Nicola Zamboni、Charles Boone、Michael Costanzo、Jianzhe Li、Gianni Liti、Jia-Xing Yue、Markus Ralser、Evan Williams、Mattia Zampieri、Heng Jiang、Tailin Wu、Yalin Wang、Feiran Li、Joseph Schacherer、Rui Sun、Zhaoxing Li、Yaming Deng、Yi Chen、Zhiping Xie、Huiqiang Lou、Xiaowen Wang、Linhai Xie、Han Wen、Liangyi Chen、Kai Lei、George Rosenberger、Xue Cai、Yingrui Wang、Qi Xiao、Huaizong Shen、Gaowen Liu、Lei Ma、Brenda Andrews、Hui Lu、Kiryl Piatkevich、Yi Zhu、Lei Bai、Yizhi Cai、Yuping Chen、Weinan E、Ge Gao、Fuchu He、Luonan Chen、Stan Z Li、Hongwu Ma、Liang Qiao、Lars M Steinmetz、Leihan Tang、Tang Tang、Xiaofan Zhang、Jing Yang、Yifan Yang、Kaicheng Yu、Jianyang Zeng、Yefeng Zheng、Bowen Zhou、Tiannan Guo

作者机构

  • Affiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, School of Medicine, School of Future Biomedicine, Westlake University, Hangzhou, China.
  • Westlake Center for Intelligent Proteomics, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, China.
  • Research Center for Industries of the Future, School of Life Sciences, Westlake University, Hangzhou, China.
  • Center for Machine Learning Research, Peking University, Beijing, China.
  • AI for Science Institute, Beijing, China.
  • National Engineering Laboratory for Big Data Analysis and Applications, Beijing, China.
  • Center for Data Science, Peking University, Beijing, China.
  • Shanghai Artificial Intelligence Laboratory, Shanghai, China.
  • Research Institute of Intelligent Complex Systems, Fudan University, Shanghai, China.
  • Stanford Genome Technology Center, Stanford University, Palo Alto, CA, USA.
  • Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
  • Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.
  • The Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.
  • Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Institute of Research on Cancer and Ageing of Nice (IRCAN), Faculté de Médecine, Nice, France.
  • State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Biochemistry, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Exploratory Diagnostic Sciences, Berlin Institute of Health at Charité, Berlin, Germany.
  • Center for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Max Planck Institute for Molecular Genetics, Berlin, Germany.
  • Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
  • Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Department of Artificial Intelligence, School of Engineering, Westlake University, Hangzhou, China.
  • Biomedical Research Core Facilities, Westlake University, Hangzhou, China.
  • Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, China.
  • Université de Strasbourg, CNRS, Inserm, IGBMC UMR 7104-UMR-S 1258, Illkirch, France.
  • State Key Laboratory of Microbial Metabolism and Joint International Research Laboratory of Metabolic and Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
  • South China Hospital, Health Science Center, Guangdong Key Laboratory of Genome Instability and Disease Prevention, Shenzhen University School of Medicine, Shenzhen, China.
  • State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Research Unit of Proteomics Driven Cancer Precision Medicine (Chinese Academy of Medical Sciences), Beijing, China.
  • International Academy of Phronesis Medicine (Guangdong), Guangzhou, China.
  • DP Technology Co. Ltd., Beijing, China.
  • Beijing Advanced Center of RNA Biology (BEACON), Peking University, Beijing, China.
  • State Key Laboratory of Medical Proteomics, Beijing, China.
  • State Key Laboratory of Membrane Biology, Beijing Key Laboratory of Cardiometabolic Molecular Medicine, Institute of Molecular Medicine, Center for Life Sciences, College of Future Technology, Peking University, Beijing, China.
  • Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, China.
  • Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China.
  • Institute of Biology, Westlake Institute for Advanced Study, Hangzhou, China.
  • Bruker Switzerland AG, Faellanden, Switzerland.
  • Zhejiang Key Laboratory of Structural Biology, School of Life Sciences, Westlake University, Hangzhou, China.
  • Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
  • National Biomedical Imaging Center, College of Future Technology, Peking University, Beijing, China.
  • State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic and Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
  • SJTU-Yale Joint Center of Biostatistics and Data Science, National Center for Translational Medicine, MoE Key Lab of Artificial Intelligence, AI Institute Shanghai Jiao Tong University, Shanghai, China.
  • Shanghai Engineering Research Center for Big Data in Pediatric Precision Medicine, NHC Key Laboratory of Medical Embryogenesis and Developmental Molecular Biology & Shanghai Key Laboratory of Embryo and Reproduction Engineering, Shanghai, China.
  • School of Life Sciences, Westlake University, Hangzhou, China.
  • Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, China.
  • Manchester Institute of Biotechnology, University of Manchester, Manchester, UK.
  • Generative and Synthetic Genomics, Wellcome Sanger Institute, Cambridge, UK.
  • Shenzhen Institute of Synthetic Biology, Chinese Academy of Sciences, Shenzhen, China.
  • Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
  • School of Mathematical Sciences, Peking University, Beijing, China.
  • State Key Laboratory of Gene Function and Modulation Research, Biomedical Pioneering Innovative Center (BIOPIC) and Beijing Advanced Innovation Center for Genomics (ICG), School of Life Sciences, Center for Bioinformatics (CBI), Peking University, Beijing, China.
  • School of Mathematical Sciences and School of AI, Shanghai Jiao Tong University, Shanghai, China.
  • AI Laboratory, Research Center for Industries of the Future, Westlake University, Hangzhou, China.
  • Biodesign Center, State Key Laboratory of Engineering Biology for Low-Carbon Manufacturing, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, China.
  • National Center of Technology Innovation for Synthetic Biology, Tianjin, China.
  • Department of Chemistry, Fudan University, Shanghai, China.
  • Genome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
  • DZHK (German Centre for Cardiovascular Research), Heidelberg, Germany.
  • Stanford Genome Technology Center, Palo Alto, CA, USA.
  • Center for Interdisciplinary Studies, Westlake University, Hangzhou, China.
  • Wuhan Metware Biotechnology Co. Ltd., Wuhan, China.
  • Guangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, China.
  • State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences Beijing, Beijing Institute of Lifeomics, Beijing, China.
  • School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China.
  • Autolab, Westlake University, Hangzhou, China.
  • School of Engineering, Research Center for Industries of the Future, Westlake University, Hangzhou, China.
  • Medical Artificial Intelligence Laboratory, Westlake University, Hangzhou, China.
  • Department of Electronic Engineering, Tsinghua University, Beijing, China.
  • Affiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, School of Medicine, School of Future Biomedicine, Westlake University, Hangzhou, China. guotiannan@westlake.edu.cn.
  • Westlake Center for Intelligent Proteomics, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, China. guotiannan@westlake.edu.cn.
  • Research Center for Industries of the Future, School of Life Sciences, Westlake University, Hangzhou, China. guotiannan@westlake.edu.cn.

技术路线

多模态生物数据与机理知识、亚细胞结构、动态状态三类数据支柱 → 细胞复杂性分解为八个功能模块(遗传、代谢、结构系统),各模块为领域AI工具并由大语言模型调度层协调

最近 5 个完整年度引用趋势

0110202102022020230202402025

不含 2026 年,仅展示最近 5 个完整年度。

数据来源:openalex更新时间:2026/10/29 12:32
AI 靶点发现基础研究Cell

AI-driven discovery of GPNMB CAR T cells as a multi-cancer therapy.

8 次引用趋势数据不足

研究开发了一种人工智能驱动的CAR-T细胞靶点发现方法,通过整合人皮肤癌与健康组织的单细胞RNA测序数据集筛选候选靶点,并利用公共数据集优化肿瘤组成、组织特异性及临床可行性,再以大语言模型优先排序和提名治疗潜力靶点。糖蛋白非转移性黑色素瘤蛋白B(GPNMB)为最常被提名的靶点,其在血液肿瘤和实体瘤中的表达得到验证。研究构建了靶向人GPNMB的CAR-T细胞,在小鼠单核母细胞白血病、黑色素瘤和结直肠腺癌模型中显示出强效抗肿瘤活性。研究建立了可扩展的CAR-T细胞靶点发现流程,并支持将GPNMB靶向CAR-T细胞作为多癌种治疗手段的转化。

为什么值得关注

暂未整理

查看扩展信息

完整作者

Daniel J Baker、Leon M Frommer、Ugur Uslu、Kisha K Patel、Daniel Zhu、Nils W Engel、James M George、Wencao Zhao、Samuel I Kim、Lisa Sun、Christopher Roselle、Philipp C Rommel、Regina M Young、Jonathan A Epstein、Sikander Hayat、Zoltan Arany、Carl H June

作者机构

  • Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Cardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: bakerdj@upenn.edu.
  • Department of Medicine 2, RWTH Aachen University, Medical Faculty, Aachen, Germany.
  • Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, 97080 Würzburg, Germany.
  • Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
  • Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
  • Cardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Cardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Institute for Regenerative Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Department of Cell and Developmental Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Medicine 2, RWTH Aachen University, Medical Faculty, Aachen, Germany; Cardiovascular Research Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Windreich Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: shayat@ukaachen.de.
  • Cardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: zarany@upenn.edu.
  • Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: cjune@upenn.edu.

技术路线

单细胞RNA测序数据(人类皮肤癌与健康组织)整合→AI驱动候选靶点筛选,结合公共数据集优化肿瘤组成、组织特异性与临床可行性→大语言模型优先排序与提名→GPNMB跨血液与实体瘤表达验证→构建人源GPNMB CAR T细胞→单核细胞白血病、黑色素瘤和结直肠腺癌小鼠模型抗肿瘤活性验证

最近 5 个完整年度引用趋势

0110202102022020230202402025

不含 2026 年,仅展示最近 5 个完整年度。

数据来源:openalex更新时间:2026/10/29 12:32
AI 靶点发现基础研究Nature

Accelerating scientific discovery with Co-Scientist.

157 次引用引用上升

研究旨在加速科学发现,研究人员开发了基于Gemini的多智能体人工智能系统Co-Scientist,用于结构化科学思维与假说生成。该系统根据研究目标和已有科学证据提出可验证的新颖研究假说,其设计包括多智能体架构与异步任务执行框架,以及通过锦标赛式进化过程实现假说生成的自我改进。自动评估显示,测试时计算扩展可持续提升假说质量。研究在药物重定位、新靶点发现和抗菌药物耐药机制解释三个生物医学应用中开展验证;Co-Scientist识别出急性髓系白血病的新药物重定位候选物和协同联合疗法,并经体外实验验证。真实世界验证表明,Co-Scientist有望加速科学发现。

为什么值得关注

暂未整理

查看扩展信息

完整作者

Juraj Gottweis、Wei-Hung Weng、Alexander Daryin、Tao Tu、Petar Sirkovic、Artiom Myaskovsky、Grzegorz Glowaty、Felix Weissenberger、Alessio Orlandi、Dan Popovici、Anil Palepu、Keran Rong、Ryutaro Tanno、Khaled Saab、Fan Zhang、Jacob Blum、Andrew Carroll、Kavita Kulkarni、Nenad Tomašev、Dina Zverinski、Ivor Rendulic、Elahe Vedadi、Florian Hasler、Luka Rimanic、Marina Boia、Ivan Budiselic、Ben Feinstein、Mathias Bellaiche、Tom Sheffer、Jan Freyberg、Jeremy Ratcliff、Ottavia Bertolli、Katherine Chou、Avinatan Hassidim、Burak Gokturk、Amin Vahdat、Yuan Guan、Vikram Dhillon、Eeshit Dhaval Vaishnav、Byron Lee、Tiago R D Costa、José R Penadés、Gary Peltz、Yossi Matias、James Manyika、Demis Hassabis、Yunhan Xu、Pushmeet Kohli、Annalisa Pawlosky、Alan Karthikesalingam、Vivek Natarajan

作者机构

  • Google Cloud AI Research, Zurich, Switzerland. juro@google.com.
  • Google DeepMind, Mountain View, CA, USA. ckbjimmy@google.com.
  • Google Cloud AI Research, Zurich, Switzerland.
  • Google DeepMind, Mountain View, CA, USA.
  • Google Research, Mountain View, CA, USA.
  • Stanford University School of Medicine, Palo Alto, CA, USA.
  • Houston Methodist Hospital, Houston, TX, USA.
  • Sequome, San Francisco, CA, USA.
  • Fleming Initiative and Imperial College London, London, UK.
  • Google DeepMind, Mountain View, CA, USA. pushmeet@google.com.
  • Google Research, Mountain View, CA, USA. apawlosky@google.com.
  • Google DeepMind, Mountain View, CA, USA. alankarthi@google.com.
  • Google DeepMind, Mountain View, CA, USA. natviv@google.com.

技术路线

研究目标与科学证据输入→多智能体(基于Gemini)异步任务执行与锦标赛演化生成/批判/优化假设→自动化评估(测试时算力扩展)→三个生物医学应用(药物重定位、新靶点发现、抗菌素耐药机制解释)→急性髓系白血病候选药物与协同组合的体外实验验证

最近 5 个完整年度引用趋势

0153002021020220202302024302025

不含 2026 年,仅展示最近 5 个完整年度。

数据来源:openalex更新时间:2026/10/29 12:32
AI 靶点发现基础研究Nucleic acids research

ARKbase: Antimicrobial Resistance Knowledgebase1.0.

4 次引用趋势数据不足

抗菌药物耐药(AMR)被视为“静默大流行”,是紧迫的全球健康挑战之一。为此,研究者开发了ARKbase,一个面向世界卫生组织细菌重点病原体的整合型、经人工整理并增值的AMR知识库。该知识库包含数据库模块、洞察模块和比较分析模块三个核心部分,提供经整理的数据以及利用定制流程分析所得数据。数据库模块收录经整理的参考基因组、泛基因组及抗菌药物敏感性试验(AST)谱;洞察模块含14个子模块,提供耐药基因、毒力因子、结构注释、宿主—病原互作、生物合成基因簇、已知抗生素、蛋白—蛋白互作、药物靶点、共靶点、药物—靶点互作、机器学习模型及抗生素暴露转录组数据集等深度注释;比较分析模块提供简易界面,用于比较不同重点病原体的耐药基因、毒力因子和药物靶点。数据经质量核查,AST按CLSI标准、基因组序列按EUCAST指南整理,并遵循FAIR数据原则。ARKbase是首个同时聚焦WHO重点病原体和AWaRe分类的综合知识库,有助于以综合证据方法整体理解AMR。

为什么值得关注

AI 辅助短评,基于标题和摘要整理

ARKbase整合了WHO优先病原体的基因组、药敏及多组学注释,模块化设计便于比较ARG、毒力因子和药物靶点。其遵循CLSI、EUCAST和FAIR原则进行数据质控,但摘要未说明任何实验验证或独立基准测试。作为知识库,其实际效用取决于数据覆盖度、更新机制及用户评估,需进一步验证其分析流程的准确性。

查看扩展信息

完整作者

Simran Gambhir、Shweta Pandey、Harsh Bajetha、Jasleen Kaur、Ankita Das、Gnanasekar Pranavathiyani、Rupali Aggarwal、Upasana Maity、Suhani Dange、Vipin Singh、Mayur Zarkar、Raghav Sankhdher、Bhupender Singh、Shivani Seth、Anshu Bhardwaj

作者机构

  • Bioinformatics Centre, CSIR-Institute of Microbial Technology, Chandigarh 160036, India.
  • Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
  • UM-DAE Centre for Excellence in Basic Sciences, School of Biological Sciences, University of Mumbai Kalina Campus, Mumbai 400098, India.
  • Life Sciences Department, J.C. Bose University of Science and Technology, YMCA, Sector 6, Mathura road, Faridabad Haryana 121006, India.
  • Independent Researcher, IMTECH Housing, Sector 39A, Chandigarh 160036, India.

技术路线

数据/样本:聚焦WHO细菌优先病原体的参考基因组、泛基因组、AST谱、转录组数据集及多类注释资源(ARG、毒力因子、结构、宿主-病原互作、BGC、药物靶点等) → 分析:使用自建流程进行数据分析和注释,并按CLSI AST标准、EUCAST基因组序列指南及FAIR原则进行质量检查与人工整理

最近 5 个完整年度引用趋势

0110202102022020230202412025

不含 2026 年,仅展示最近 5 个完整年度。

数据来源:openalex更新时间:2026/10/29 12:32
AI 靶点发现方法学eLife

Harnessing AlphaFold to reveal hERG channel conformational state secrets.

14 次引用引用上升

为设计安全、选择性且有效的新疗法,需深入理解药物靶点的结构与功能,而跨膜离子通道蛋白离散构象状态的解析尤为困难。KV11.1(hERG)承载主要心脏复极电流Ikr,是药物安全性筛查中重要的抗靶点,其失活态药物相互作用与心律失常风险升高相关,药物还可能在通道关闭时被捕获。本研究显示,引入精心选择的结构模板可引导AlphaFold预测走向不同功能状态。该靶向建模通过与实验数据比较得到验证,包括状态依赖性结构特征、分子对接药物相互作用及分子动力学模拟的离子传导特性。AlphaFold不仅预测了阻止离子传导的hERG失活机制,还揭示了解释失活期间药物结合增强的新分子特征。利用AlphaFold推导的状态可改善计算筛查与实验药物亲和力的一致性,弥补传统单状态模型的不足。通过映射关闭、开放和失活状态的残基相互作用网络,研究识别出驱动状态转换的关键残基,并得到既往诱变研究验证。该方法为整合深度学习蛋白结构预测与实验验证建立了新基准,并提供了广泛适用的策略。

为什么值得关注

编辑短评

本文提出以结构模板引导AlphaFold预测hERG通道离散构象,并与实验数据、对接和分子动力学模拟比较验证,进而用于计算筛选及残基网络分析。其思路对状态依赖性药物安全评估有潜在价值,但验证主要依赖计算与既往数据比对,缺乏新实验结构解析;筛选改善幅度与普适性需独立评估。

查看扩展信息

完整作者

Khoa Ngo、Pei-Chi Yang、Vladimir Yarov-Yarovoy、Colleen E Clancy、Igor Vorobyov

作者机构

  • Center for Precision Medicine and Data Science, University of California, Davis, Davis, United States.
  • Department of Physiology and Membrane Biology, University of California, Davis, Davis, United States.
  • Department of Anesthesiology and Pain Medicine, University of California, Davis, Davis, United States.
  • Department of Pharmacology, University of California, Davis, Davis, United States.

技术路线

结构模板引导AlphaFold预测hERG通道不同构象状态→与实验数据(状态依赖性结构特征、分子对接药物相互作用、分子动力学离子传导特性)比较验证→利用预测状态进行计算筛选并与实验药物亲和力比较→映射闭合/开放/失活态的残基相互作用网络,关键残基由既往突变研究验证

最近 5 个完整年度引用趋势

0240202102022020230202442025

不含 2026 年,仅展示最近 5 个完整年度。

数据来源:openalex更新时间:2026/10/30 06:00
AI 靶点发现综述Cancer cell

New horizons at the interface of artificial intelligence and translational cancer research.

55 次引用引用上升

人工智能正日益成为分析多组学数据的计算策略应用于癌症研究。单细胞与空间 profiling 技术的进步显著加深了对肿瘤生物学的理解,人工智能方法现被用于加速转化研究,包括靶点发现、生物标志物识别、患者分层和治疗反应预测。然而,人工智能融入临床工作流程仍然有限,既带来挑战也带来机遇。本综述讨论人工智能在多组学分析和转化肿瘤学中的应用,强调其在推进生物学发现和为临床决策提供信息方面的作用。重点关注领域包括细胞异质性、肿瘤微环境相互作用和人工智能辅助诊断。综述探讨了可重复性、人工智能模型可解释性和临床整合等挑战,并关注应对这些障碍的策略。这些进展共同凸显了人工智能与多组学在提升精准肿瘤学和推动癌症护理进步方面的潜力。

为什么值得关注

暂未整理

查看扩展信息

完整作者

Josephine Yates、Eliezer M Van Allen

作者机构

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Institute for Machine Learning, Department of Computer Science, ETH Zürich, Zurich, Switzerland; ETH AI Center, ETH Zurich, Zurich, Switzerland; Swiss Institute for Bioinformatics (SIB), Lausanne, Switzerland.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA; Division of Medical Sciences, Harvard University, Boston, MA, USA; Parker Institute for Cancer Immunotherapy, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: eliezerm_vanallen@dfci.harvard.edu.

技术路线

多组学数据集(单细胞与空间 profiling 数据) → AI 计算分析(细胞异质性、肿瘤微环境互作、靶点发现、生物标志物识别、患者分层、治疗反应预测、AI 辅助诊断)

最近 5 个完整年度引用趋势

0101902021020220202302024192025

不含 2026 年,仅展示最近 5 个完整年度。

数据来源:openalex更新时间:2026/10/29 12:33
页